Background: Prostate-specific antigen (PSA) is the most important marker for prostate cancer, but PSA concentrations determined by various assays can differ significantly because of differences in specificity of the antibodies used. To identify epitopes recognized by various monoclonal antibodies (MAbs) to PSA, we have isolated peptides that react with the paratopes of these. Methods: Six anti-PSA MAbs representing three major epitope groups were screened with five cyclic phage display peptide libraries. After selection, the peptide sequences were determined by sequencing of the relevant part of viral DNA. Binding of the phage peptides to the MAbs was monitored by immunoassay. Results: For each MAb, several paratope-binding peptides with distinct sequence motifs were identified, but only ϳ10% showed similarity with the PSA sequence. Some of these correctly predicted the location of the epitopes. By sequential panning of the library with two closely related MAbs, we identified peptides reacting equally with both MAbs. When analyzed against a large panel of PSA MAbs, the peptides generally showed restricted specificity toward the MAb used for selection, but some peptides bound to several related MAbs. Conclusions: Most of the cyclic peptides selected with PSA MAbs are specific for the MAb used for selection and do not resemble any sequence on the antigen. Peptides reactive with two MAbs recognizing the same epitope can be obtained by sequential panning. This method can be used to predict the location of some epitopes, but additional methods are needed to confirm the result.
(1 ). Prostate-specific antigen (PSA) 1 is a serine protease secreted by the epithelial cells of the prostate (2 ) . It is a reliable marker for monitoring treatment of prostate cancer, but it is also widely used for early diagnosis and screening (3, 4 ) . Serum PSA is frequently increased in patients with benign prostatic hyperplasia, and in a screening setting, only approximately one-third of those with increased PSA have prostate cancer (4 ) . PSA exists in circulation in various molecular forms, including several PSA-inhibitor complexes and isoforms of free PSA, and the use of assays for these forms can improve the clinical accuracy of PSA determination (5) (6) (7) (8) (9) . The PSA concentrations measured by different assays vary significantly, which can be attributable to differences in standardization or specificity of the antibodies used toward various molecular forms of PSA (10 ) . Furthermore, some PSA antibodies can also recognize human kallikrein 2 (hK2), which may affect the measured PSA concentrations. hK2 shows ϳ80% identity with PSA at the amino acid level (11) (12) (13) , and like PSA, hK2 is a prostate-derived proteinase that has been shown to be a useful marker for prostatic disease (14, 15 ) . PSA has been shown to contain six major epitope regions, which are exposed to a varying extent in different forms of PSA (16 ) . To develop assays with highly defined specificity, it is important to know the epitopes of the antibodies used in the assay. Use of antibodies with defined specificities facilitates the development of assays that produce comparable results and the design of assays specific for variant forms of the antigen. Although the epitopes of PSA have been studied extensively (16 -22 ) , the locations of only a few of the epitopes have been localized on the primary sequence of PSA. Amino acid residues forming linear epitopes can be identified by synthetic peptide epitope mapping, in which short chemically synthesized peptides covering the whole coding sequence of the antigen are used to identify the regions interacting with the monoclonal antibodies (MAbs) (23 ), as also described for PSA (19, 20 ) . An alternative method is to screen peptide libraries to identify paratope-binding peptides, i.e., peptides binding to the antigen-binding site, and to compare the structures of these with that of the antigen (21, 24 -26 ) . We studied whether paratope-binding peptides to MAbs against PSA isolated by screening cyclic phage display peptide libraries can be used to predict the structure of PSA epitopes.
Materials and Methods antibodies and proteins
The MAbs 5E4, 9C5, and 4G10 were developed with the following protocol. BALB/c mice were immunized with 10 -30 g of purified PSA by intraperitoneal injection with Freund's complete adjuvant. PSA was purified from human seminal fluid as described previously (27 ) . A booster dose of 10 g was given after 4 weeks, and then additional boosters of 100 and 150 g were given 1 and 2 days after the first booster, respectively. After the final booster, the splenic lymphoid cells of the mice were fused with the mouse myeloma cell line P3x63-Ag8.653 (American Type Culture Collection). The fused cells were harvested in HAT medium supplemented with interleukin-6 for 4 weeks, after which the cells were harvested in HT medium. PSA antibody production was screened by use of an immunofluorometric assay (IFMA) in microtiter wells coated with rabbit anti-mouse immunoglobulin. Briefly, 25 L of hybridoma supernatants plus 200 L of IFMA assay buffer (6 ) were incubated for 1 h in the wells, after which the wells were washed twice and 10 ng of Eu 3ϩ -labeled PSA in 200 L of assay buffer was added. After additional incubation for 30 min, the wells were washed four times, and 200 L of enhancement solution (PerkinElmer-Wallac) was added. After incubation for 5 min, the fluorescence was measured. The MAbs produced were purified by affinity chromatography using protein G columns (Amersham Biosciences).
Anti-PSA MAbs H117 and H50 were obtained from Abbott Diagnostics. Antibody 5A10 was from PerkinElmer-Wallac. The characteristics of the ISOBM workshop panel of anti-PSA MAbs have been described in detail elsewhere (16 ) . Anti-phage MAb was a kind gift from Dr. Petri Saviranta (University of Turku, Turku, Finland). Anti-phage polyclonal antibody was purchased from Amersham Biosciences. Peptides were synthesized by standard Merrifield solid-phase chemistry. The phage peptide libraries were a kind gift from Dr Erkki Koivunen (University of Helsinki, Helsinki, Finland).
selection of phage peptides
Screening of the phage display peptide libraries was performed essentially as described previously (28 ) . Libraries with the structures CX7C, CX8C, CX10C, CX3CX3CX3C, and CX3CX4CX2C, where C is cysteine and X is any of the 20 naturally occurring amino acids, were used. A pool of these libraries containing 10 11 
IFMAs
The solid-phase antibodies used in the IFMA were coated on microtitration wells at a concentration of 5 mg/L in TBS for 16 h at 22°C. The solution was then discarded, and the wells were saturated with 10 g/L bovine serum albumin in TBS for 3 h at 22°C. The antibodies used as tracers were labeled with a Eu 3ϩ chelate as described previously (28 ) . The assay buffer was TBS, pH 7.7, containing 33 mol/L bovine serum albumin and 1 mol/L bovine globulin.
The binding of individual phage clones to MAbs was tested by phage IFMA. In this assay, 15 L of phage (10 9 -10 10 infectious particles) and 200 L of assay buffer were added to wells coated with each MAb. After incubation for 1 h, the wells were washed and filled with 200 L of assay buffer containing 50 ng of a Eu 3ϩ -labeled anti-phage MAb recognizing the M13 coat protein of the phage. After incubation for 60 min, the wells were washed four times, and enhancement solution (Perkin-ElmerWallac) was added. Fluorescence was quantified with a 1234 DELFIA Research fluorometer (Perkin-Elmer-Wallac). The detection limit was defined as the fluorescence signal obtained with phage containing unrelated peptide ϩ3 SD.
The binding specificity of the phage peptide to the antigen-binding regions of the mAbs was confirmed by Clinical Chemistry 48, No. 12, 2002 showing that PSA inhibited the binding of phage to antibodies. Briefly, 15 L of each phage clone and 0.3-300 ng of PSA purified from seminal fluid were pipetted into a well coated with each mAb. After incubation of phage and PSA for 2 h, the protocol for phage IFMA was followed. The binding specificity of synthetic peptides was confirmed by showing that they competed with PSA for binding to antibodies. Briefly, 0 -120 g of peptide in 200 L of assay buffer was pipetted into a well coated with MAb. After incubation for 1 h, 5 ng of PSA was added and incubated for 30 min. Inhibition of PSA binding was quantified by PSA IFMA as described (31 
Results

identification of antibody-binding peptides
The MAbs studied were chosen on the basis of crossinhibition characteristics to include three pairs of closely related antibodies. The peptides isolated with the six MAbs contained characteristic motifs and consensus amino acids (Table 1 ), but only 9 of 100 peptides displayed sequence identity with PSA, defined as at least three identical amino acids within a window of four amino acids. Binding of the peptides to MAbs was inhibited by PSA, showing that they were paratope specific ( Fig. 1) .
The epitopes of MAbs 5E4 and H117 have been mapped to the N-terminal region of PSA (amino acid residues 3-11) by synthetic peptide mapping and crossinhibition studies (16, 20 ) . However, most of the peptides developed against these antibodies resembled neither PSA nor each other. This indicated that the peptides recognized structures in the paratope that do not participate in antigen binding or that the epitopes were different and mainly determined by the three-dimensional structure of PSA. To identify peptides reacting with two MAbs recognizing the same epitope, we developed a sequential panning strategy. The peptides identified by this strategy using MAbs 5E4 and H117 did not resemble the peptides selected separately (Table 1) . Two peptides, CPSVDGG-WTC (VI-13 and VI-20) and CHSACSKHCFVHC (VI-15 and VI-22), were obtained irrespective of the order in which the MAbs were used for selection. In peptides VI-13 and VI-14, the motif GGWTC was similar to the sequence GGWEC comprising residues 3-7 in the NH 2 terminus of mature PSA (Fig. 2) . Furthermore, in peptides VI-15 and VI-21, the motif CSKH was similar to the sequence CEKH comprising residues 7-10 in PSA (Fig. 2) . Thus, the structures of these peptides suggest that the epitope recognized by MAbs 5E4 and H117 comprises residues 3-10 in mature PSA. All phage peptides isolated by use of MAb 5E4 alone contained the structure PXD-FXFL. This motif was not present in peptides selected by MAb H117 alone, which contained the motif WXXXPXE (Table 1) . Among MAb 5E4-selected peptides, peptides CAPWWGC  H50  III-1  CSGIAPWLC  H50  III-8  CGPGIDSWVC  H50  III-9  CGPGIRSWVC  H50  III-12  CDYMPLVDNC  H50 and 9C5  III-14  CEGIAVWLC  H50 and 9C5  III-15  CTRYSGYWVC  H50 and 9C5  III-17  CTQMNGYWIC  H50 and 9C5  III-20  CLYDHLC  H50 and 9C5  III-25  CILLYNDCC  9C5  III-28  CFFGNWNFC  9C5 and H50  III-37  CWNWNLHISC  9C5 and H50  III-38  CYFKNWNFC  9C5 and H50 III-39 CVRSCISDCELRC a The sequences of the peptides analyzed further are shown. The peptides were isolated by panning with each MAb or by sequential panning, in which the library was first panned using one MAb, after which the eluate was panned with another related MAb. The peptide sequences were determined by sequencing the relevant part of the viral DNA. MAbs 5E4 and H117 belong to epitope group VI, MAbs 5A10 and 4G10 to group I, and MAbs H50 and 9C5 to group III (16 ) . The sequences of all peptides isolated (n ϭ 100) are available as a data supplement with the online version of this article at http://www.clinchem.org/ content/vol48/issue12/.
VI-9 and VI-12 contained the sequence EFL corresponding to PSA amino acid residues 140 -142; a similar sequence, DFL, was present in four other peptides, and the FL sequence was present in all 12 peptides. A synthetic peptide (corresponding to the sequence of phage peptide VI-12) containing the EFL sequence inhibited the binding of PSA with MAb 5E4 in a dose-dependent manner (Fig.  3) , confirming that this peptide and PSA bind to same site on the MAb. Among MAb H117-selected peptides, peptide VI-18 contained the PEE sequence (residues 138 -140 in PSA), and the PXE motif was present in three of the four peptides. Thus, these MAbs recognize the same amino acids in region 3-10 and different amino acids from the region 138 -142 (PEEFL; Fig. 2 ). Interestingly, in the three-dimensional model of PSA (29 ) , the PEEFL sequence is located close to the N-terminal epitope (Fig. 4) . These results suggest that amino acids 138 -142 form part of a noncontinuous epitope together with amino acids 3-10 in the N-terminal region. Group I MAbs 5A10 and 4G10 bind to an epitope specific for free PSA, which in PSA-serpin complexes is covered by the inhibitors (16, 32 ) . Some MAbs in this group have been shown to bind to linear epitopes comprising amino acids 80 -91 in PSA, which form part of the so-called kallikrein loop (16, 20 ) , but most of them react only weakly with reduced, intact PSA, suggesting that they are mainly conformation dependent. MAbs 5A10 and 4G10 inhibit each other efficiently, but MAb 4G10 has been shown to cross-react with complexed PSA approximately two-to fivefold more than does 5A10 (33, 34 ) , suggesting that the epitopes of these MAbs are not identical. When we selected with 4G10 and sequentially with 4G10 and 5A10, we found the motifs YPFW, WWW, and PWW (Table 1) , but these are not found in PSA. 
Clinical Chemistry
However, when we selected with MAb 5A10 and sequentially with 5A10 and 4G10, we frequently found the WGS and TVXXAW motifs. Peptide I-9 contained the sequence SWGSSRC, which is similar to the PSA sequence SWG-SEPC (amino acids 204 -210 in PSA; Fig. 2) . Furthermore, WGS, WG, or GS motifs were present in 7 of 22 peptides isolated. In agreement with this, Michel et al. (21 ) have found by screening peptide libraries that the SWG site forms part of the epitope of MAbs specific for free PSA. Amino acids 204 -207 (SWGS) form the edge of the groove containing the active site residues of PSA (29 ) opposite the region 80 -91 on the other side of the groove. Peptide I-16 contained the sequence HPYKV, which is similar to the PSA sequence HPQKV (amino acids 164 -168 in PSA), which is located adjacent to amino acids 204 -207 and borders to the predicted binding site of group III MAbs (Fig. 2) . It may thus form part of the epitope for MAbs specific for free PSA. Further support for the location of the epitope as predicted by phage display peptides can be obtained by analyzing whether the predicted epitope regions differ between PSA and hK2 and accounting for whether the MAb reacts with PSA only or with both PSA and hK2. hK2 shares 80% identity with PSA (11) (12) (13) , and many PSA antibodies are known to recognize hK2, showing that several epitopes in PSA and hK2 are identical (16, 35 ) . Thus, the location of the epitope of MAb 5A10 in the 164 -168 region in PSA is further supported by the facts that this region differs between PSA and hK2 (HPQKV and YSEKV, respectively) and that MAb 5A10 does not react with hK2 (16 ) . Thus, these results suggest that the epitopes for MAbs belonging to group I may comprise residues on three different loops, i.e., amino acids 80 -91 (20 ) , 164 -168, and 204 -207.
MAbs H50 and 9C5 bind to epitopes located remote from the active site and are considered to be mainly conformation dependent (16 ) . These MAbs show highly similar binding characteristics, but only H50 shows strong reactivity with hK2 (16, 36 ) . The peptides isolated by panning with MAb H50 and sequentially with MAbs H50 and 9C5 frequently contained the structures GIXXW or GYW, whereas in peptides isolated by use of MAb 9C5 and sequentially with MAbs 9C5 and H50, the NWN motif was found repeatedly. Peptides III-8 and III-9 (H50 selection) contained the sequences PGIDS and PGIRS, respectively, which are similar to the sequence PGDDS in PSA (amino acids 89 -93; Fig. 2 ). This region partially overlaps amino acids 80 -91 in PSA, which is the previously identified binding site for MAbs specific for free PSA (20 ) . Furthermore, MAb H50 binds strongly to both PSA and hK2, but the amino acid sequence 89 -93 in these differs (PGDDS and PDEDS in PSA and hK2, respectively). Thus, it is unlikely that the PGDDS sequence is part of the epitope for these MAbs. In peptide III-12 (H50 selection), the sequence PLVDN is similar to the PSA sequence PLVCN (amino acids 192-196 in PSA; Fig. 2 ). This sequence is identical in PSA and hK2, and it is adjacent to epitope region 151-155 in the three-dimensional model of PSA, which previously has been predicted to be a binding site for MAbs belonging to this epitope group. Thus, these results suggest that the epitopes for group III MAbs comprise at least two different loops, i.e., amino acids 151-155 (20 ) and 192-196. reactivity of the peptides with isobm MAbs To study whether the epitopes found were recognized by other MAbs, we studied the reactivity of 19 peptides with a panel of MAbs from the ISOBM workshop. The peptides studied were isolated by sequential panning using MAb pairs 5E4/H117 (group VI), 4G10/5A10 (group I), and H50/9C5 (group III).
The reactivity of three group VI peptides showing similarity with amino acids 3-10 in PSA was studied with 13 group VI MAbs (Table 2 ). Seven MAbs bound to these peptides, suggesting that amino acids 3-10 in PSA form part of the epitope recognized by most MAbs in this group. Six of the MAbs did not bind any of these peptides, suggesting that these amino acids are not a major part of their epitopes or that the motif is not present in correct conformation for these MAbs.
The reactivity of six group I peptides (I-8, I-15, I-30, I-31, I-32, and I-35) was studied with 14 group I MAbs. These peptides showed highly restricted specificity and reacted only with the primary selection MAb, i.e., peptides I-8 and I-15 reacted only with MAb 5A10, and peptides I-30, I-31, I-32, and I-35 reacted only with MAb 4G10.
The reactivity of eight group III peptides was tested with 14 MAbs from epitope group III (Table 3) 
Discussion
The main antigenic regions of PSA recognized by mouse antibodies have been studied extensively (16, 17, 20, 22 ) , but not much is known about the fine structure of the epitopes. In this study, we isolated peptides binding specifically with the paratope regions of six PSA MAbs and studied their reactivity with a large panel of PSA antibodies.
Alignment of the peptides with the PSA sequence revealed several binding motifs, but most of the isolated peptides did not resemble any part of PSA. These may represent mimotopes, i.e., antigenic mimics, or they may be structurally unrelated to PSA, reflecting the polyspecific nature of the binding region of an antibody (37 ) . Thus, although MAbs are usually considered to be specific for a certain antigen, the paratope can also bind structures that do not resemble the original immunogen. Even if MAbs have rarely been shown to bind strongly to unrelated natural antigens, cross-reactivity with a totally unrelated protein has been observed with an antibody prepared against a synthetic peptide (38 ). The polyspecificity can be explained by the fact that the paratope consists of ϳ20 amino acids, but only a few of these participate in antigen binding, and water molecules can fill the remaining space between the paratope and epitope. Thus, the same paratope can contain several subsites for different epitopes, and amino acids in the paratope can form strong bonds with peptides unrelated to the immunogen (37, 39 ) . The polyspecific nature of paratopes toward unrelated peptides has also been demonstrated by Keitel et al. (40 ) and Kramer et al. (41 ) , who used x-ray structural data of three peptides complexed with an anti-p24 (HIV-I) MAb.
In our study, only ϳ10% of the peptides showed similarity with PSA. Some of these corresponded to earlier identified epitopes, whereas others contained new motifs adjacent to earlier described ones. Thus, they may well form part of the epitope. Antibodies 5E4 and H117 identified the same N-terminal epitope (amino acids 3-10) as was found in previous studies for MAbs in this group (20 ) , but they also appeared to react with amino acids in the 138 -142 region. These antibodies also react with hK2 (16 ), and regions 3-10 and 138 -142 are identical in PSA and hK2 (11, 12 ) , further supporting the involvement of these residues in the epitopes. Results from other groups have suggested that most of the MAbs that bind both PSA and hK2 recognize nonconformational linear epitopes (35 ) . The N-terminal part of PSA appears to form a fairly long linear N-terminal epitope (residues 3-10) and thus may be the major mediator of binding of MAbs in this group. However, regions 3-10 and 138 -142 reside within 15-20 Å from each other, and amino acids within this distance can be in contact with the paratope (37 ) . Thus, it is conceivable that the epitopes of some group VI MAbs comprise residues 3-10 and 138 -142. MAbs 5E4 and H117 bind peptides similar to PSA 3-10 and 138 -142, but the epitopes around amino acids 138 -142 are overlapping rather than identical. Parhami-Seren et al. (42 ) also identified overlapping epitopes for two related MAbs against streptokinase by screening peptide libraries. Interestingly, in previous synthetic peptide epitope mapping studies, MAb H117 did not react with any synthetic linear peptide derived from the PSA sequence (20 ) , although it has been shown to compete efficiently with other group VI MAbs (16 ) . Thus, it is likely that the synthetic peptides used by Piironen et al. (20 ) could not adopt the correct conformation required for strong binding with MAb H117.
We also found some paratope-specific peptides showing sequence similarity with PSA, but the suggested epitope locations were not in agreement with those in previous studies. In a single peptide (III-8), the sequence identity was not compatible with previous epitope assignments, suggesting that the sequence similarity was attributable to chance.
A key factor in the protocol for isolating peptides resembling the linear epitope in the NH 2 terminus of PSA was the introduction of sequential panning with two MAbs. With this method, peptides reacting with both selection MAbs (5E4 and H117) were obtained. However, with MAb pairs 9C5/H50 and 5A10/4G10, no peptides reactive with both MAbs were found, which suggests that the epitopes for these MAbs do not contain common residues although they block the binding of each other.
Synthetic peptide mapping studies have suggested that the binding sites for MAbs specific for free PSA reside in the regions 50 -69 (19 ) and 80 -91 (20 ) . In the study of Piironen et al. (20 ) , all seven free-PSA MAbs reacted strongly with peptides containing the 84 -91 sequence. Some binding of MAbs was observed to peptides containing the sequence 50 -67, but strong reaction with these peptides was observed for only two MAbs recognizing both free and complexed PSA. Furthermore, Jette et al. (43 ) identified the sequence PSA 51-55 as an epitope for a "total PSA specific" MAb by use of both synthetic peptide epitope mapping and peptide library screening. Michel et al. (21 ) suggested on the basis of peptide library screening that the epitopes of MAbs specific for free PSA include amino acid residues from PSA regions 53-59, 145-148, and 204 -207. Our results also suggested that amino acids 204 -208 may form part of the epitope for such MAbs, but no peptides resembling the two other sequences were found. In the three-dimensional model, these amino acids form a relatively wide loop, and it is possible that the cyclic peptides used in our study are too tightly coiled to mimic such a loop.
No peptides that bound strongly to MAb H50 were found by Piironen et al. (20 ) by use of synthetic peptide epitope mapping, but the binding sites of related MAbs were mapped to the 151-155 region. We did not find any peptides with similarity to this region by screening with the two related MAbs, H50 and 9C5. However, a peptide showing similarity with the 192-196 region was identified after screening with MAb H50, and this region is adjacent to region 151-155 in the three-dimensional model of PSA. Furthermore, the 192-196 region is identical in PSA and a The assay was as described in footnote a of Table 2 .
hK2, and MAb H50 is reactive with both PSA and hK2 (16 ) .
reactivity of the peptides with isobm MAbs
Previous studies on reactivity of paratope-binding peptides with MAbs showing highly similar specificity suggested that peptides generally show restricted specificity toward the selection MAb (44 ) . This was also the case with peptides to group I MAbs, which were specific for free PSA, i.e., each peptide bound only to the MAb used to isolate it. The peptides selected with group III MAbs also showed restricted specificity. Most of them bound to 1-3 of the 14 MAbs specific for this region. In contrast, the peptides selected with group VI MAbs recognized many antibodies. Two peptides bound to one-half (7 of 13) of the MAbs included. These results suggest that amino acids 3-10 form an immunodominant region that can be mimicked by the fairly short cyclic peptides. The restricted specificity of the peptides to MAbs in other groups may indicate larger variability in epitope specificity. Thus, although some epitope regions can be subgrouped by use of paratope-binding peptides, the general utility of this approach for epitope identification is limited. Many peptides bearing no relationship with the immunogen (PSA) bound strongly to the paratopes. Apparently these binding specificities are not displayed by natural human antigens, as evidenced by the very high specificity of MAbs when used for clinical purposes. However, the unexpected reactivity of a MAb to BRCA1 with semenogelin may be an example of such polyspecificity (38 ) . A less dramatic but more common demonstration of this polyspecificity is the nonspecific inhibition of antigenantibody binding exerted by proteins. This phenomenon contributes to the well-known matrix effect that affects all immunoassays (45 ) . The nonspecific interactions between various proteins in clinical samples and the paratope must be much weaker that that of the specifically selected peptides, and it can usually be eliminated by diluting the sample (45 ).
In conclusion, this study shows that screening with peptide libraries can be used to define both linear and noncontinuous epitopes, but the assignment of an epitope region needs to be confirmed by complementary methods. Furthermore, although MAbs are highly specific when used in clinical assays, the paratope region can bind strongly to several unrelated peptide structures. However, strong nonspecific binding may be revealed only by phage display peptides, whereas it appears to be very rare in natural samples.
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